NICO Launches New Xenon Light Technology Enabling Enhanced Visualization in Minimally Invasive Neurosurgery
The NOVUS couples xenon light with the Myriad resection tool, providing precise light exactly where the surgeon needs it. The NOVUS also provides, for the first time ever, automated and intraoperative tissue harvesting for post-procedural analysis in the modern molecular era.
Over 900 neurosurgeons have attended similar courses in the U.S., Canada and Singapore on Advances in Subcortical Neurosurgery using Minimally Invasive Parafascicular Surgery (MIPS) supported by the BrainPath Approach, NICO's systems approach to addressing both primary and secondary tumors and hemorrhagic stroke -- the deadliest, costliest and most debilitating form of stroke with an annual worldwide incidence rate of 2.1 million.
New Technology in Treating Hemorrhagic Stroke Video1: Video 2: Video 3: Video 4: To date, a total of 18 peer-reviewed papers and abstracts that included 221 cases have been published on the clinical experiences and outcomes when using...
NICO Launches Investigator Initiated Study Program to Increase Scientific Data Supporting Minimally Invasive Neurosurgery
NICO has invested more than $8 million in clinical research supporting true minimally invasive neurosurgery approaches using automated technologies for subcortical and skull base procedures.
NICO Corporation Adds to Strong Intellectual Property Portfolio of 200+ with New Patent Issued Around Revolutionary BrainPath Technology
Joe Mark, Chief Technology Officer of NICO and primary inventor of its patented technologies comments: “This new issuance further protects the distinctive capabilities of the BrainPath technology and is validation by the patent office that these innovations are relevant and worthy of protecting."
6/1/18: “Our goal in funding this important trial is to find an effective treatment for appropriate patients with ICH – the deadliest, costliest and most debilitating form of stroke that currently has no surgical solution,” said Jim Pearson, president and CEO of NICO Corporation.
5/22/18: “We have performed extensive studies on extent of resection for high grade gliomas, and all the studies show that increased extent of resection and decreased residual tumor are associated with better survival and delayed recurrence,” said Kaisorn Chaichana, MD, one of the paper’s authors. “However, we have also shown that if you cause a deficit, these patients do worse regardless of your extent of resection.
12Page 1 of 2